Vertex Pharmaceuticals director sells 271 shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Vertex Pharmaceuticals Inc. (VRTX) director Sangeeta N. Bhatia sold 271 shares at $547.86 per share on November 16, 2026, under a company-approved Rule 10b5-1 trading plan entered into on August 13, 2026. After the sale, she directly held 4,653 shares.
Insider Trade Summary 10b5-1
Net Seller: 271 shares
Net Sell
1 txn
Insider
Bhatia Sangeeta N.
Role
Director
Sold
271 shs ($148K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock F1 | 271 | $547.86 | $148K |
Holdings After Transaction:
Common Stock — 4,653 shares (Direct)
Footnotes (1)
- F1. Transaction made pursuant to Dr. Bhatia's company approved trading plan under Rule 10b5-1, which was entered into on 08/13/2026.
Key Figures
Shares sold: 271 shares
Sale price: $547.86 per share
Direct shares held after sale: 4,653 shares
3 metrics
Shares sold
271 shares
November 16, 2026
Sale price
$547.86 per share
Sale on November 16, 2026
Direct shares held after sale
4,653 shares
After the November 16, 2026 sale
Key Terms
Rule 10b5-1
1 terms
Rule 10b5-1 regulatory
"under a company-approved Rule 10b5-1 trading plan"
Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.